| 000 | 01563 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515124242.0 | ||
| 264 | 0 | _c20080703 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(08)60918-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aComi, G | |
| 245 | 0 | 0 |
_aEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJun 2008 |
||
| 300 |
_a2085-92 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aQuinolones _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPulizzi, A | |
| 700 | 1 | _aRovaris, M | |
| 700 | 1 | _aAbramsky, O | |
| 700 | 1 | _aArbizu, T | |
| 700 | 1 | _aBoiko, A | |
| 700 | 1 | _aGold, R | |
| 700 | 1 | _aHavrdova, E | |
| 700 | 1 | _aKomoly, S | |
| 700 | 1 | _aSelmaj, Kw | |
| 700 | 1 | _aSharrack, B | |
| 700 | 1 | _aFilippi, M | |
| 773 | 0 |
_tLancet (London, England) _gvol. 371 _gno. 9630 _gp. 2085-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(08)60918-6 _zAvailable from publisher's website |
| 999 |
_c18056200 _d18056200 |
||